Rite Aid: Is Growth a Game Changer?

Rite Aid has seen tremendous gains with vast net income improvements, but could revenue growth spark yet another impressive stock run?

Feb 15, 2014 at 7:30AM

Rite Aid (NYSE:RAD) has seen a near-$650 million improvement to its bottom line over the last three years, without any top-line growth. Still, the company trades at a deep discount to its peers Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS), but could revenue growth be key in closing that gap?

Rite Aid: Where it has been and what's occurred
To fully understand Rite Aid's recovery, and what's driven its stock price from $1 to nearly $6, you have to understand where the company had been and what it has accomplished.

If you rewind to late 2012, many were betting on bankruptcy, as it had been years since the company had earned a quarterly profit, and it was continuously losing market share to peers CVS and Walgreen.

Furthermore, from 2009 till 2012 the company's debt-to-assets ratio increased annually, from 70% to more than 85%, meaning the company appeared more set for a death spiral than a 500% recovery.

Then, the company posted its first quarterly profit in four years, of $61.9 million, which was the spark that lit this fire. Since then, the company has posted a quarterly profit in each following earnings report, and this profit alone has driven the stock to such large gains.

How it accomplished the recovery
Rite Aid's recovery can be attributed to many things: Some will say it's the company's loyalty program, and others will say the closing, remodeling, and relocating of unprofitable stores is finally starting to pay off.

However, one reason that all agree on is the patent cliff and the introduction of new generic drugs, which is something that management for Rite Aid, Walgreen, and CVS all note as being instrumental in boosting margins.

The patent cliff is a five-year period between 2011 and 2016 in which $133 billion of branded drugs are being introduced to the market as generics via patent expirations. These generics give pharmacies more pricing power, are bought in bulk, and return higher profits per script than brand drugs.

As a result, pharmacies have surged.

What's the next step?
One fact that many often forget is that Rite Aid achieved its massive gains despite no growth.

If we look back to the three quarters that sparked gains from $1, starting Dec. 20, 2012, comparable-store sales for the pharmacy were as followed:

Fiscal Quarter

Date

Comparable-Store Sales

Third

Dec. 20, 2012

(1.5%)

Fourth

April 11, 2013

(2%)

First

June 20, 2013

(2.5%)

As you can see, comparable-store sales actually worsened during this period, but it didn't stop shares of Rite Aid from surging more than 200%. That said, take a look at Rite Aid's comparable-store sales for the last three months, via monthly reports.

Month and Year

Comparable-Store Sales

November 2013

2.8%

December 2013

2.9%

January 2014

1.8%

Clearly, Rite Aid is starting to achieve growth, something that has not been a staple in its incredible stock rally. Therefore, with the addition of growth, this could spark the next phase of gains for Rite Aid, a stock with room to run a lot higher.

Not comparable to its peers
Rite Aid's recent production of growth is not to the same level as its peers Walgreen and CVS.

In Walgreen's last quarter, it saw revenue growth of 5.9%, and like Rite Aid, it continues to see margin and net income improvements, up 68% in the same quarter. If we look to analyst expectations, Walgreen should grow another 4.8% this year.

CVS is expected to grow at the same sub-5% rate this year. Furthermore, CVS' last quarter mirrored Walgreen as well: The company grew sales by 5.8% and net income 24.7% year over year.

Therefore, CVS and Walgreen are both in better fundamental shape than Rite Aid... and are priced as such.

This fact is an important point to remember when assessing these three companies and determining upside. For example, Rite Aid trades at 19 times earnings with a profit margin of 1.2%, but if Rite Aid had CVS' margin, it would trade at about six time earnings.

This brings up the point that Rite Aid also trades at just 0.2 times sales, about one-third the valuation of its peers. Hence, Rite Aid is greatly discounted from its peers likely because it lacks the growth -- and in past years, it lacked any growth.

Room to run higher with growth
So, if Rite Aid is now growing, even if it's less than 1% annually, it stands to reason that the stock deserves a greater multiple to its peers.

Perhaps CVS and Walgreen are still worth a 100% premium to sales, based on the assumption that growth is sustainable and margins will continue to rise with new generic introductions. If so, and with Rite Aid trading at one-third to one-fourth the valuation of its peers, then shares could still increase 50%.

If the market decides that Rite Aid is worthy of the same multiple as its peers based on greater upside potential, then shares of the stock could still triple or more as the company continues to grow.

The bottom line: Rite Aid still presents a lot of upside, and with its newfound level of growth, investors should anticipate further gains should.

Demystifying Obamacare for investors
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

 

Brian Nichols owns Rite Aid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers